{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:24:32Z","timestamp":1787289872948,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.gore.2026.102165","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:05:44Z","timestamp":1783782344000},"page":"102165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Quality of life and psychological outcomes with albumin-bound paclitaxel-carboplatin versus solvent-based paclitaxel-carboplatin as first-line chemotherapy in stage IC\u2013IV ovarian carcinoma"],"prefix":"10.1016","volume":"66","author":[{"given":"Nidhi","family":"Mahlawat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atal","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poorva","family":"Vias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Sawaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.gore.2026.102165_bb0005","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdr583","article-title":"Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial","volume":"23","author":"Brundage","year":"2012","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2026.102165_bb0010","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cncr.11578","article-title":"Measuring the side effects of taxane therapy in oncology","volume":"98","author":"Cella","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.gore.2026.102165_bb0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000447403","article-title":"Sexual health and quality of life assessment among ovarian cancer patients during chemotherapy","volume":"91","author":"Domenici","year":"2016","journal-title":"Oncology"},{"issue":"13","key":"10.1016\/j.gore.2026.102165_bb0020","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"31","key":"10.1016\/j.gore.2026.102165_bb0025","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102165_bb0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.gore.2026.102165_bb0035","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3802\/jgo.2015.26.2.148","article-title":"Quality of life and sexuality comparison between sexually active ovarian cancer survivors and healthy women","volume":"26","author":"Kim","year":"2015","journal-title":"J. Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.gore.2026.102165_bb0040","first-page":"1272","article-title":"First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel\/epirubicin\/carboplatin versus paclitaxel\/carboplatin: reliability and validity of EORTC QLQ-OV28","volume":"39","author":"Kristensen","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.gore.2026.102165_bb0045","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/ijgc-2021-003142","article-title":"Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-symptom benefit study","volume":"32","author":"Lee","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"31","key":"10.1016\/j.gore.2026.102165_bb0050","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016620","article-title":"Dynamic change of depression and anxiety after chemotherapy among patients with ovarian cancer","volume":"98","author":"Liu","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.gore.2026.102165_bb0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2407-12-77","article-title":"Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy","volume":"28","author":"Meraner","year":"2012","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.gore.2026.102165_bb0060","article-title":"Comparison of Hamilton depression rating scale and Montgomery-\u00c5sberg depression rating scale: baked straight from a randomized study","volume":"15","author":"Santi","year":"2023","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.gore.2026.102165_bb0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/tcrm.1.2.107.62910","article-title":"Paclitaxel chemotherapy: from empiricism to mechanism-based formulation strategy","volume":"1","author":"Scripture","year":"2005","journal-title":"Ther. Clin. Risk Manag."},{"issue":"11","key":"10.1016\/j.gore.2026.102165_bb0070","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.gore.2026.102165_bb0075","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.gore.2026.102165_bb0080","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.breast.2020.12.002","article-title":"Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer","volume":"55","author":"Tsurutani","year":"2021","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.gore.2026.102165_bb0085","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2023.34.e44","article-title":"Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study","volume":"34","author":"Wang","year":"2023","journal-title":"J. Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.gore.2026.102165_bb0090","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1200\/JCO.2005.08.147","article-title":"Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic oncology group study","volume":"23","author":"Wenzel","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.gore.2026.102165_bb0095","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2018.29.e81","article-title":"A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer","volume":"29","author":"Wilson","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102165_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1025018","article-title":"The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: a review of current evidence","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"10.1016\/j.gore.2026.102165_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/pon.6280","article-title":"Psychosocial interventions for ovarian cancer survivors: a systematic review","volume":"33","author":"Yeoh","year":"2024","journal-title":"Psychooncology"},{"issue":"11","key":"10.1016\/j.gore.2026.102165_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061967","article-title":"Quality of life in patients with breast cancer with neoadjuvant chemotherapy: a systematic review","volume":"12","author":"Zhao","year":"2022","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.gore.2026.102165_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-102770","article-title":"Omission of dexamethasone in paclitaxel premedication regimens: protocol of the DEXASTOP trial","volume":"15","author":"Zietse","year":"2025","journal-title":"BMJ Open"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:45:08Z","timestamp":1787287508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":23,"alternative-id":["S2352578926001451"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102165","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life and psychological outcomes with albumin-bound paclitaxel-carboplatin versus solvent-based paclitaxel-carboplatin as first-line chemotherapy in stage IC\u2013IV ovarian carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102165"}}